|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ITS PLASMA CLEARANCE BY 50%
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID ACTION IS POTENTIATED BY THE DRUG
|
PARACETAMOL TOXICITY RISK ARE INCREASED BY TWO FOLD IF GIVEN WITH DRUGS THAT INDUCE LIVER MICROSOMAL ENZYMES
|
ISONIAZID, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID REDUCES ITS PLASMA CLEARANCE BY 50%
|
PHENYTOIN SERUM LEVELS ARE INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
PYRAZINAMIDE HAS SYNERGISTIC ACTION WITH ISONIAZID BUT REDUCES ITS SERUM CONCENTRATION ALSO
|
INCREASED POTENTIAL FOR HEPATOTOXICITY
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
FOLIC ACID DEFICIENCY MAY PRECIPITATE WITH CONCURRENT USE
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID REDUCES ALPRAZOLAM & OTHER BENZODIAZEPINES CLEARANCE SO REDUCE ALPRAZOLAM DOSE TO 1/3
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
|
ISONIAZID BY INDUCING CYTOCHROME P450 ISOENZYMES AFFECT THE METABOLISM OF THE DRUG WITH INCREASED CHANCES OF TOXICITY
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
INSULIN REQUIREMENT IS INCREASED BY THE DRUG
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
PREDNISOLONE DECREASES ITS SERUM LEVEL
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY CAUSE CNS EFFECTS LIKE DROWSINESS & DIZZINESS WITH CONCURRENT USE
|
CYCLOSPORINE SERUM LEVELS ARE REDUCED BY THE DRUG
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY CAUSE ACUTE BEHAVIORAL & COORDINATION CHANGES IN THE PATIENT
|
ETHIONAMIDE MAY POTENTIATE THE ADVERSE EFFECTS OF OTHER ANTITUBERCULOSIS DRUGS ADMINISTERED CONCOMITANTLY
|
ETHIONAMIDE HAS BEEN FOUND TO TEMPORARILY RAISE SERUM CONCENTRATIONS OF ISONIAZID
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
KETOCONAZOLE REDUCES ITS PLASMA CONCENTRATION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
VIT B6 REQUIREMENT IS INCREASED BY THE DRUG
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
ISONIAZID MAY EFFECT VIT D METABOLISM CAUSING REDUCED SERUM LEVELS OF VIT D, CALCIUM & PHOSPHATE & ELEVATED PARATHYROID HORMONE
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|